Trend Reporting and Investigation Duties under ANMAT 8194/2023
Updated: 2026-11-12 · GRZAN Regulatory Team · Verification date 2026-10-20
1. Key takeaways
Disposición ANMAT 8194/2023 does not stop at the reporting of individual serious events under the 48-hour and 10-calendar-day thresholds. It also imposes two categories of obligations that companies most easily overlook:
- Trend reporting, which applies whenever non-serious events show a statistically significant increase in frequency or severity;
- The investigation obligation, which requires that after a report is made, an investigation and risk assessment be carried out without delay.
Together, these two obligations extend vigilance from an event-driven exercise to a data-driven one: even when no single event crosses the 48-hour or 10-day threshold, the company still bears a reporting duty if the statistics show an abnormal upward movement. A quiet product, measured month over month, can generate a reporting obligation that a single noisy incident never triggers. Companies that only look at individual cases will systematically miss this duty, and ANMAT designed the obligation precisely to catch that gap.
The practical reading of these obligations is that vigilance data must be treated as an asset in its own right. The events that individually look trivial are precisely the raw material for the trend determination, and an investigation opened after a report is not an appendix but a duty with its own timeline. A company that collects event data inconsistently, by product line or by market channel, will be unable to compute a defensible baseline, and without that baseline neither the trend judgment nor the subsequent risk assessment can be documented to a standard that survives regulatory scrutiny.
2. Legal basis
| Regulation | Reference / number | Publication date | Provisions |
|---|---|---|---|
| Good technovigilance practices | Disposición ANMAT 8194/2023 | Published October 3, 2023; effective October 4, 2023 | Trend reporting provision; investigation and risk assessment provision |
| International harmonization documents | IMDRF N43; ISO/TR 20416 | — | Documents aligned with 8194/2023 |
| National health products law | Ley 16.463 | Enacted 1964; in force | Penalty provisions |
3. Expert insights
Insight 1: Trend reporting sets no specific number of days; it sets the judgment standard of statistical significance. This effectively hands the determination responsibility to the company itself: the company must define its own baseline, set its own statistical method, and make its own determination of significance. Without a data baseline there is nothing to judge against, so the trend reporting obligation forces every registration holder to build a routine, ongoing data monitoring mechanism. A company that cannot state what its normal event rate looks like cannot demonstrate compliance with this provision, because it cannot demonstrate that any given month was or was not a significant deviation from its own history.
Insight 2: The investigation obligation is separate from the reporting obligation. After a report is filed, an investigation and risk assessment must be carried out without delay. ANMAT has the authority to request clarifications, request supplementary information, visit company premises when necessary, and bring in experts. Investigation is not a matter of filing and being done; it is systematic work that can run for weeks. The quality of the investigation record, the speed with which clarification requests are answered, and the coherence of the risk assessment with the original report are all points where regulators judge whether a company treats vigilance as a formality or as a functioning safety system.
Insight 3: Trend reporting is especially critical for software products. Hardware failures are usually discrete events, while software performance degradation tends to appear as a slow statistical drift, for example the recognition accuracy for a particular patient population gradually declining. This kind of phenomenon will not trigger the single-event thresholds; it is only captured by trend monitoring. A SaMD manufacturer that has no performance metrics in its vigilance data stream is effectively blind to the one failure mode most characteristic of its product, and the regulation’s data-driven design exists precisely to close that blindness.
Insight 4: Trend reporting effectively changes who bears the analytical burden. Under single-event reporting, the trigger is visible and dramatic, and the obligation is self-evident. Under trend reporting, the trigger hides in the statistics, and only a company that monitors its own data continuously will even perceive that an obligation has arisen. This asymmetry means that two companies with identical event histories can hold different compliance positions: the one with a functioning monitoring mechanism sees and reports the significant increase, while the one without it never forms the awareness that starts any clock. For software products this is doubly true, because a drift in performance metrics is gradual by nature and invisible to case-by-case review. The regulation’s data-driven design therefore rewards investment in analytics, and the SOP should treat the absence of a data baseline not as a neutral state but as a compliance gap in itself.
4. Practical recommendations
- Establish an event data baseline for each product line. Track monthly event counts, event type distribution, and severity distribution by product model, forming a comparable baseline against which future movements can be measured.
- Write the statistical determination method into the SOP. Define the rule for what counts as a statistically significant increase, for example an incidence rate exceeding the historical mean range for three consecutive months, so that the determination is reproducible by different assessors.
- Standardize the investigation process. Fix five elements in the SOP: investigation trigger conditions, participating roles, deadlines, report format, and conclusion archiving.
- Add performance metric monitoring for software products. Bring accuracy, sensitivity, and other key indicators into the scope of trend monitoring rather than counting only adverse events.
5. Verification checklist
- □ An event data baseline has been established by product model
- □ The determination method for statistically significant increase has been written into the SOP
- □ The five elements of the investigation process, namely trigger, roles, deadlines, format, and archiving, have been fixed
- □ A response mechanism for ANMAT clarification or supplementary information requests has been prepared
- □ Software products have brought performance metrics into the scope of trend monitoring
- □ An archiving mechanism for trend reports and investigation records has been established
Regulatory information verified as of October 29, 2026.
In Argentina, GRZAN operates a wholly owned subsidiary that can act as the registration holder and importer for foreign manufacturers, directly handling classification assessment, pathway selection, GMP and CFS documentation chains, Spanish-language technical documentation and label localization, HELENA submissions and deficiency responses, as well as BONITA import notifications, ARGOS vigilance system operation, change maintenance, and 5-year renewal planning.
The GRZAN regulatory team consists of professionals with many years of hands-on international registration experience, tracking the developments of regulators worldwide. All external content follows the drafting standard of conclusions first, traceable basis, and verifiable numbers. For a market access plan tailored to your specific product for Argentina or the MERCOSUR region, contact the GRZAN regulatory team at info@grzanglobal.com.
Disclaimer
Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.
About GRZAN
GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.
GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.
Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.
What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.
Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.
Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.
Take your devices global with GRZAN
We work with manufacturers worldwide to open new markets with a clear regulatory pathway.
Contact us